Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

American Cancer Society: Cancer Facts & Figures 2007. 2007, Alanta, GA: American Cancer Society Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0. Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-867. 10.1038/nature01322. Meylan E, Tschopp J, Karin M: Intracellular pattern recognition receptors in the host response. Nature. 2006, 442: 39-44. 10.1038/nature04946. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-436. 10.1038/nature04870. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005, 5: 749-759. 10.1038/nri1703. de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038/nrc1782. Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016/j.ccr.2005.02.013. de Visser KE, Coussens LM: The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006, 13: 118-137. Coussens LM, Werb Z: Inflammatory cells and cancer: think different!. J Exp Med. 2001, 193: F23-F26. 10.1084/jem.193.6.F23. Osada T, Clay TM, Woo CY, Morse MA, Lyerly HK: Dendritic cell-based immunotherapy. Int Rev Immunol. 2006, 25: 377-413. 10.1080/08830180600992456. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L: Links between innate and cognate tumor immunity. Curr Opin Immunol. 2007, 19: 224-231. 10.1016/j.coi.2007.02.003. David H: Rudolf Virchow and modern aspects of tumor pathology. Pathol Res Pract. 1988, 183: 356-364. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004, 21: 137-148. 10.1016/j.immuni.2004.07.017. Boshoff C, Weiss R: AIDS-related malignancies. Nat Rev Cancer. 2002, 2: 373-382. 10.1038/nrc797. Penn I: Posttransplant malignancies. Transplant Proc. 1999, 31: 1260-1262. 10.1016/S0041-1345(98)01987-3. Euvrard S, Kanitakis J, Claudy A: Skin cancers after organ transplantation. N Engl J Med. 2003, 348: 1681-1691. 10.1056/NEJMra022137. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, et al: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995, 60: 183-189. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B: De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001, 7 (11 Suppl 1): S109-S118. 10.1053/jlts.2001.28645. Pham SM, Kormos RL, Landreneau RJ, Kawai A, Gonzalez-Cancel I, Hardesty RL, Hattler BG, Griffith BP: Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg. 1995, 60: 1623-1626. 10.1016/0003-4975(95)00120-4. Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet. 1995, 346: 796-798. 10.1016/S0140-6736(95)91618-0. Gallagher B, Wang Z, Schymura MJ, Kahn A, Fordyce EJ: Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol. 2001, 154: 544-556. 10.1093/aje/154.6.544. Oluwole SF, Ali AO, Shafaee Z, DePaz HA: Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature. J Surg Oncol. 2005, 89: 23-27. 10.1002/jso.20171. McHeyzer-Williams MG: B cells as effectors. Curr Opin Immunol. 2003, 15: 354-361. 10.1016/S0952-7915(03)00046-3. Youinou P, Jamin C, Saraux A: B-cell: a logical target for treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: 318-328. Whitford PGW, Cambell AM: Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. Cancer Lett. 1992, 61: 157-164. 10.1016/0304-3835(92)90174-T. Morton BA, Ramey WG, Paderon H, Miller RE: Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res. 1986, 46 (4 Pt 2): 2121-2126. Wernicke M: Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. Surg Gynecol Obstet. 1975, 140: 919-924. Urdiales-Viedma M, Nogales-Fernandez F, Martos-Padilla S, Sanchez-Cantalejo E: Correlation of histologic grade and lymph node status with some histopathologic discriminants in breast cancer. Tumori. 1986, 72: 43-51. Shimokawara I, Imamura M, Yamanaka N, Ishii Y, Kikuchi K: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: an immunoperoxidase study with anti-human T- and B-cell sera. Cancer. 1982, 49: 1456-1464. 10.1002/1097-0142(19820401)49:7<1456::AID-CNCR2820490724>3.0.CO;2-#. Lee AH, Happerfield LC, Bobrow LG, Millis RR: Angiogenesis and inflammation in ductal carcinoma in situ of the breast. J Pathol. 1997, 181: 200-206. 10.1002/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP: Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001, 61: 7889-7899. Punt CJ, Barbuto JA, Zhang H, Grimes WJ, Hatch KD, Hersh EM: Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes. Cancer Immunol Immunother. 1994, 38: 225-232. Coronella-Wood JA, Hersh EM: Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother. 2003, 52: 715-738. 10.1007/s00262-003-0409-4. Wang BL, Springer GF, Kaufman MW: Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen–Friedenreich)/Tn antigens in human breast carcinoma. J Histochem Cytochem. 1996, 44: 187-191. Jaume JC, Portolano S, Prummel MF, McLachlan SM, Rapoport B: Molecular cloning and characterization of genes for antibodies generated by orbital tissue-infiltrating B-cells in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1994, 78: 348-352. 10.1210/jc.78.2.348. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C: Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest. 1998, 102: 938-946. Colombo M, Dono M, Gazzola P, Roncella S, Valetto A, Chiorazzi N, Mancardi GL, Ferrarini M: Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol. 2000, 164: 2782-2789. Kim HJ, Krenn V, Steinhauser G, Berek C: Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol. 1999, 162: 3053-3062. Tomer Y, Sherer Y, Shoenfeld Y: Autoantibodies, autoimmunity and cancer [review]. Oncol Rep. 1998, 5: 753-761. Tan EM, Shi FD: Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol. 2003, 134: 169-177. 10.1046/j.1365-2249.2003.02259.x. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997, 15: 3363-3367. Fernandez Madrid F: Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. Cancer Lett. 2005, 230: 187-198. 10.1016/j.canlet.2004.12.017. Sheikh KM, Quismorio FP, Friou GJ, Lee YT: Ductular carcinoma of the breast: serum antibodies to tumor-associated antigens. Cancer. 1979, 44: 2083-2089. 10.1002/1097-0142(197912)44:6<2083::AID-CNCR2820440619>3.0.CO;2-E. Lee YT, Sheikh KM, Quismorio FP, Friou GJ: Circulating anti-tumor and autoantibodies in breast carcinoma: relationship to stage and prognosis. Breast Cancer Res Treat. 1985, 6: 57-65. 10.1007/BF01806011. Wong PY, Staren ED, Tereshkova N, Braun DP: Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res. 1998, 76: 95-103. 10.1006/jsre.1998.5301. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J: Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res. 1992, 12: 1463-1466. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, Syrjanen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992, 28A: 859-864. 10.1016/0959-8049(92)90134-N. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P, et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003, 349: 546-553. 10.1056/NEJMoa012782. Page DL, Jensen RA, Simpson JF: Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat. 1998, 51: 195-208. 10.1023/A:1006122716137. Badwe RA, Thorat MA, Parmar VV: Sentinel-node biopsy in breast cancer. N Engl J Med. 2003, 349: 1968-1971. 10.1056/NEJM200311133492017. author reply 1968–1971 Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP: Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005, 2: e284-10.1371/journal.pmed.0020284. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126/science.1129139. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58: 3491-3494. Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ: Th1/Th2 cells in inflammatory disease states: therapeutic implications. Expert Opin Biol Ther. 2004, 4: 1887-1896. 10.1517/14712598.4.12.1887. Munk ME, Emoto M: Functions of T-cell subsets and cytokines in mycobacterial infections. Eur Respir J Suppl. 1995, 20: 668s-675s. Romagnani S: The Th1/Th2 paradigm. Immunol Today. 1997, 18: 263-266. 10.1016/S0167-5699(97)80019-9. Stout RD, Bottomly K: Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. J Immunol. 1989, 142: 760-765. Parker DC: T cell-dependent B cell activation. Annu Rev Immunol. 1993, 11: 331-360. Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF: Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000, 165: 6024-6028. Fallarino F, Gajewski TF: Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol. 1999, 163: 4109-4113. Lowes MA, Bishop GA, Crotty K, Barnetson RS, Halliday GM: T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol. 1997, 108: 914-919. 10.1111/1523-1747.ep12292705. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA: IL-12 induces T helper 1-directed antitumor response. J Immunol. 1997, 158: 3359-3365. Hu HM, Urba WJ, Fox BA: Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol. 1998, 161: 3033-3041. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU: Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996, 42: 1-8. 10.1007/s002620050244. Ostrand-Rosenberg S, Grusby MJ, Clements VK: Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol. 2000, 165: 6015-6019. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F: A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol. 1998, 160: 5869-5873. Tan TT, Coussens LM: Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007, 19: 209-216. 10.1016/j.coi.2007.01.001. Johansson M, Tan T, de Visser KE, Coussens LM: Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem. 2007, 101: 918-926. 10.1002/jcb.21230. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006, 24: 5373-5380. 10.1200/JCO.2006.05.9584. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H: Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 2003, 63: 4516-4520. Lim HW, Hillsamer P, Banham AH, Kim CH: Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005, 175: 4180-4183. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A: CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004, 112: 258-267. 10.1016/j.clim.2004.04.003. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A, Thiel A: Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol. 2005, 35: 2452-2458. 10.1002/eji.200526069. Chen W: Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front Biosci. 2006, 11: 1360-1370. 10.2741/1889. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-949. 10.1038/nm1093. Ellner JJ: Suppressor cells of man. Clin Immunol Rev. 1981, 1: 119-214. Columba-Cabezas S, Serafini B, Ambrosini E, Sanchez M, Penna G, Adorini L, Aloisi F: Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol. 2002, 130: 10-21. 10.1016/S0165-5728(02)00170-4. Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol. 1983, 3: 295-315. 10.1007/BF00915791. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003, 33: 420-425. 10.1046/j.1365-2362.2003.01152.x. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D: Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol. 2004, 57: 630-636. 10.1136/jcp.2003.014498. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, Okamura J, Sakai M, Okamoto S: Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer. 1999, 2: 26-32. 10.1007/s101200050017. Sparmann A, Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004, 6: 447-458. 10.1016/j.ccr.2004.09.028. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 1999, 13: 1382-1397. de Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005, 7: 411-423. 10.1016/j.ccr.2005.04.014. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001, 193: 727-740. 10.1084/jem.193.6.727. Lin EY, Pollard JW: Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004, 256: 158-168. discussion 168–172, 259–269 Imada A, Shijubo N, Kojima H, Abe S: Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J. 2000, 15: 1087-1093. 10.1034/j.1399-3003.2000.01517.x. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196: 254-265. 10.1002/path.1027. Benitez-Bribiesca L, Wong A, Utrera D, Castellanos E: The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem. 2001, 49: 1061-1062. Snell GD: Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor; a review. Cancer Res. 1957, 17: 2-10. Kaliss N: Immunological enhancement of tumor homografts in mice: a review. Cancer Res. 1958, 18: 992-1003. Agassy-Cahalon L, Yaakubowicz M, Witz IP, Smorodinsky NI: The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. Immunol Lett. 1988, 18: 181-189. 10.1016/0165-2478(88)90017-X. Siegel CT, Schreiber K, Meredith SC, Beck-Engeser GB, Lancki DW, Lazarski CA, Fu YX, Rowley DA, Schreiber H: Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med. 2000, 191: 1945-1956. 10.1084/jem.191.11.1945. Schreiber H, Wu TH, Nachman J, Rowley DA: Immunological enhancement of primary tumor development and its prevention. Semin Cancer Biol. 2000, 10: 351-357. 10.1006/scbi.2000.0331. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW: Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002, 62: 7042-7049. Barbera-Guillem E, May KF, Nyhus JK, Nelson MB: Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia. 1999, 1: 453-460. 10.1038/sj.neo.7900054. Hogarth PM: Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol. 2002, 14: 798-802. 10.1016/S0952-7915(02)00409-0. Ravetch JV, Bolland S: IgG Fc receptors. Annu Rev Immunol. 2001, 19: 275-290. 10.1146/annurev.immunol.19.1.275. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL: Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res. 2001, 61: 8298-8305. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66: 11238-11246. 10.1158/0008-5472.CAN-06-1278. Society AC: Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4: 71-78. 10.1038/nrc1256. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I: IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 2002, 100: 1728-1733. Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001, 13: 459-463. 10.1093/intimm/13.4.459. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005, 5: 263-274. 10.1038/nrc1586. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999, 20: 158-160. 10.1016/S0167-5699(98)01435-2. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001, 166: 678-689. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004, 53: 64-72. 10.1007/s00262-003-0443-2. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM: Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001, 166: 5398-5406. Yang L, Debusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004, 6: 409-421. 10.1016/j.ccr.2004.08.031. Pistoia V, Corcione A: Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Stem Cells. 1995, 13: 487-500. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23: 549-555. 10.1016/S1471-4906(02)02302-5. Mantovani A, Allavena P, Sica A: Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004, 40: 1660-1667. 10.1016/j.ejca.2004.03.016.